Laigo Bio secures €11.5 million in seed funding to advance its innovative SureTAC™ targeted protein degradation technology for oncology and autoimmune disorders.

Target Company Overview

Laigo Bio, based in Utrecht, the Netherlands, is an innovative biotechnology firm focused on developing advanced therapies using its proprietary SureTAC™ technology for targeted degradation of membrane proteins. This unique platform has the potential to revolutionize treatment options in oncology and autoimmune diseases by addressing previously deemed 'undruggable' targets. The company has successfully raised €11.5 million in seed financing, which will be utilized to propel the development of its oncology programs and three immunology candidates through early clinical phases.

Under the leadership of Dr. Matthew Baker, who has a substantial background in inflammatory and oncology drug development, Laigo Bio aims to transform its SureTAC™ candidates into effective therapies. Dr. Baker brings a wealth of experience, having held various senior roles in the biotech sector, and is committed to achieving significant milestones in the company's research and clinical objectives.

Industry Overview in the Netherlands

The Netherlands is emerging as a leading hub for biotechnology and life sciences, benefiting from a robust ecosystem that includes strong academic institutions, research organizations, and a vibrant startup culture. This country is known for its innovative ap